Highlights {#Sec1}
==========

Proteomic analysis of synapses isolated from Alzheimer's disease and control subject brains identifies over 5500 proteins in human synapses.In silico analysis reveals region-specific decreases in proteins involved in synaptic and mitochondrial function and increases in proteins involved in neuroimmune signaling and intracellular signaling in AD.The apolipoprotein E4 risk gene is associated with exacerbated changes in synaptic proteins in AD.

Introduction {#Sec2}
============

Dementia poses one of the biggest societal challenges of the twenty-first century. Over 50 million people are living with dementia worldwide, it costs over \$800 billion per year to care for them, and there are currently no disease modifying treatments \[[@CR54]\]. One of the barriers to developing effective therapies for Alzheimer's disease, the most common cause of dementia, lies in the lack of a comprehensive understanding of the brain changes that cause neurodegeneration. In particular, a key knowledge gap is not yet understanding how genetic risk factors contribute to disease pathogenesis \[[@CR35]\]. Extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, and severe brain atrophy are the major neuropathological hallmarks of AD \[[@CR45]\]. There are many genetic risk factors for developing sporadic AD, the strongest of which is inheritance of the apolipoprotein E epsilon 4 allele (*APOE*4). Inheritance of one copy of *APOE*4 is associated with a 3 fold increase in disease risk and inheritance of two copies with an over 10 fold increased risk \[[@CR9]\]. In addition to its known roles in Aβ production and clearance, we and others have observed that apoE protein accumulates in synapses \[[@CR3], [@CR22], [@CR27], [@CR50]\], which is important as synapse loss is the strongest pathological correlate with cognitive decline in AD \[[@CR13], [@CR48], [@CR51]\]. ApoE4 causes more synaptic loss around plaques when expressed in mouse models of familial AD \[[@CR22]\]. Using high resolution imaging in human post-mortem brain tissue, we similarly observed exacerbated synapse loss in *APOE*4 carriers and further that apoE4 is associated with more accumulation of oligomeric Aß at synapses \[[@CR24], [@CR27]\]. More recent data implicates *APOE*4 in tau mediated neurodegeneration \[[@CR47]\] and also inflammatory *TREM2* mediated microglial phenotypes \[[@CR28]\], which may be important for synapse degeneration \[[@CR52]\]. Further highlighting the importance of APOE to AD progression, the Christchurch mutation in *APOE3* was recently observed to be associated with delayed disease onset in a person with a familial AD mutation in presenilin 1 \[[@CR2]\] .

Recent data from postnatal human brain samples shows that proteomic datasets can reveal differences in proteins that are not observed in RNA expression data, arguing the importance of building strong resource datasets at the level of protein in human diseases \[[@CR7]\]. Thus far there have been several proteomic studies of human AD brain tissue (Additional file [1](#MOESM1){ref-type="media"}: Table S1), but a comprehensive dataset on human synaptic proteins examining the effects of *APOE* genotype in AD remains unavailable.

In order to further our understanding of how *APOE* may be influencing synaptic vulnerability in AD, we have performed a comprehensive proteomic study of human post-mortem brain tissue through a series of molecular comparisons allowing us to assess the relative contribution of both regional vulnerability and *APOE* variants to AD pathogenesis. Although our study is in postmortem tissue which has inherent limitations including looking at a snapshot of the end stage of the disease, the inclusion of a less affected brain region allows some novel insight into changes that may be occurring in synapses earlier in the degenerative process. We provide a unique proteomic resource identifying over 5500 proteins in human synaptoneurosome preparations. These preparations enrich remaining synapses in the brain and unlike examination of total homogenates allow specific examination of change in synaptic proteins without the confound of synapse loss \[[@CR49]\]. Additionally, we highlight multiple proteins and molecular pathways that are modified in AD with brain region and *APOE* genotype status. In silico analysis reveals that proteins involved in glutamatergic synaptic signalling and synaptic plasticity are decreased in AD with temporal cortex (which has high levels of pathology) being more severely affected than occipital cortex (which has lower levels of pathology) and *APOE*4 carriers more affected than *APOE*3 carriers. Alterations in glial proteins important for neuroimmune signalling were also detected using in silico analysis, and further investigation revealed a host of proteins involved in the complement cascade are not only found in human synapses but are increased in AD compared to control brain. In addition to providing a resource for the field, our data support the hypothesis that *APOE* genotype plays an important role in synaptic dysfunction and degeneration in AD. The proteins and pathways identified as altered in this study can in future be investigated in more detail for their potential as therapeutic intervention points to delay or prevent synaptic alterations and the consequential symptoms contributing to dementia.

Methods {#Sec3}
=======

Subjects {#Sec4}
--------

Use of human tissue for post-mortem studies has been reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian, approval number 15-HV-016). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (16/ES/0084).

Fresh frozen brain tissue for proteomics and paraffin embedded tissue for examination of pathology was provided from superior temporal gyrus (BA41/42) and primary visual cortex (BA17). Tissue was requested from clinically diagnosed AD and control subjects. All cases were examined by a neuropathologist, and after the proteomics results were returned, it was noted that one of the AD cases was neuropathologically classified as frotntotemporal dementia with tau-associated corticobasal degeneration (Table [1](#Tab1){ref-type="table"}). The pooled design of the study precludes exclusion of this case post-hoc but also reduces inter-individual heterogeneity \[[@CR25], [@CR36]\]. However, pooled analyses on difficult sample types such as serum have also been reported to be associated with false positive and false negative results \[[@CR37]\]. While this has not been a problem in any of our previous analyses of synaptically enriched fractions, it does highlight the need for validation of results. Table 1Subject characteristics. We observe the expected decrease in brain weight in AD (2-way ANOVA effect of disease F(1,29) = 9.018, P = 0.0055, no significant effect of genotype). The control APOE3/4 group is not age matched. Age is significantly different in AD vs control (2-way ANOVA effect of disease F (1, 29) = 17.4, P = 0.0003, \* Tukey's multiple comparison test control APOE3/4 significantly different from AD APOE3/4 age p = 0.002). There are no differences in age between AD APOE3/4 and AD APOE4/4 cases. There are no significant differences of disease or genotype in post mortem interval (PMI) or brain pH.MRC BBN numberClinical diagnosisApoE genotypeSex (f,m)Age, yPMI, hbrain weight, gbrain pHBraak Stageneuropath diagnosis and co-morbiditiesBBN_14395ctrl3/3f744115206.30control, Mild degree of small vessel diseaseBBN_20122ctrl3/3m597415006.10control, No significant abnormalitiesBBN_22612ctrl3/3m617013006.10control, No significant abnormalitiesBBN\_ 24340ctrl3/3m535314006.50control, Significant atherosclerosis in larger vessels, mild small vessel diseaseBBN001.26495ctrl3/3m783912906.17Icontrol, mild Alzheimer's Disease pathologyBBN001.28402ctrl3/3m794915036.33Icontrol, mild Alzheimer\'s pathology, mild WM pathology, Moderate non-amyloid SVD, Encephalopathy, hepaticBBN001.28406ctrl3/3m797214376.13IIcontrol, mild Alzheimer\'s pathollgy. Moderate arteriolar CAA , WM pathology, Mild non-amyloid SVDBBN001.28793ctrl3/3f797212195.95IIcontrol, mild Alzheimer\'s pathology, moderate WM pathology, moderate non-amyloid SVD**group medians (IQR)*n*** **= 82,676 (18.5)61.5 (25)1418 (203)6.15 (0.2)**BBN_15258AD3/3m658013356.1VIAlzheimer\'s Disease, LBD neocrotical subtypeBBN_19595AD3/3m875814206.5VIAlzheimer\'s Disease, CAA, SVD with lacunar infarctsBBN_19994AD3/3f878912705.9VIAlzheimer\'s Disease, sCAA, Vascular disease lacunar, thrombus, embolusBBN_22223AD3/3f878312006.7IVAlzheimer\'s Disease, cerebral haemorrhage, vascular disease lacunarBBN_BBN_24527AD3/3m817411606.1VIAlzheimer\'s Disease, Vascular Disease lacunarBBN001.28410AD3/3f6210910296.04VIAlzheimer\'s Disease, Mild arteriolar CAA,Moderate non-amyloid SVDBBN001.28771AD3/3m859111835.95VIAlzheimer\'s disease, Severe arteriolar CAA , WM pathology moderate, Moderate non-amyloid SVDBBN_28785AD3/3f78769605.9Corticobasal degeneration FTLD, WM pathology, mild. Moderate non-amyloid SVD**group medians (IQR)*n*** **= 84,483 (12.25)81.5 (14)1191.5 (159)6.07 (0.27)**BBN_15221ctrl3/4m5311416506.10control, No significant abnormalitiesBBN_15809ctrl3/4m589014705.90control, mild small vessel diseaseBBN_16425ctrl3/4m619912706.20control, evidence of cerebrovascular disease, no infarctsBBN_20593ctrl3/4m6052146060control, no significant abnormalitiesBBN_20120ctrl3/4m539714006.40control, no significant abnormalitiesBBN_22629ctrl3/4f595312806.30control, no significant abnormalitiesBBN_2555ctrl3/4m746613506.30control, small vessel lipohyalinosis, large vessel athersclerosis**group medians (IQR)*n*** **= 71,659 (5)\*90 (38.5)1400 (150)6.2 (0.25)**BBN_10591AD3/4m86761470VIAlzheimer\'s Disease, small vessel diseaseBBN_15810AD3/4f739610906.2VIAlzheimer\'s Disease, vascular diseaseBBN_15811AD3/4f814114576.3VIAlzheimer\'s Disease, sCAA, Intracerebral haemorrhage, vascular diseaseBBN_19690AD3/4m575812005.9VIAlzheimer\'s disease,BBN_23394AD3/4f885911656.3VIAlzheimer\'s Disease, sCAA, Intracerebral haemorrhage, vascular disease lacunarBBN_24322AD3/4m8010114106VIAlzheimer's Disease, sCAABBN_24526AD3/4m796513006.05VIAlzheimer's DiseaseBBN_25739AD3/4f854513755.77VIAlzheimer's Disease, sCAA, focal TDP43 within the entorhinal cortex.BBN001.26718AD3/4m787413676.13VIAlzheimer\'s disease, moderate non amyloid arteriolar CAABBN_26732AD3/4m766614676.48VIAlzheimer\'s disease, Moderate non amyloid arteriolar SVD, Severe arteriorlar CAA, Limbic Lewy body disease**group medians (IQR)*n*** **= 104,679.5 (7.5)65.5 (17.3)1371 (220.3)6 (0.3)**

*APOE* genotyping {#Sec5}
-----------------

DNA was extracted from \~ 25 mg of cerebellum for each case using the QIAamp DNA mini kit (Qiagen, Hilden, Germany), which was used as per the manufacturer's instructions. Polymerase chain reaction (PCR) was performed on the extracted DNA. 10 μl of 2x Master mix (Promega, Madison, WI) was combined with 1 μl of primer stock (20 μM forward primer, 20 μM reverse primer), 2 μl of DMSO (Sigma-Aldrich, St Louis, MO), 6 μl ddH~2~O and 1 μl of isolated DNA. The forward primer was 5'taagcttggcacggctgtccaagg3' and the reverse primer 5'acagaattcgccccggcctggtacactgcc3' (Fig. [2](#Fig2){ref-type="fig"}.2a). *APOE* ε2, *APOE* ε3, and *APOE* ε4 plasmids (generously donated by Dr. E Hudry) were also amplified by PCR to use at as reference and were treated in the same way as unknown samples throughout. PCR product was digested using the restriction endonuclease HhaI (New England Biolabs, Ipswich, MA). For this 0.5 μl of enzyme, 2.5 μl of 10x CutSmart buffer (New England Biolabs, Ipswich, MA) and 2 μl of ddH~2~O were added to each PCR reaction tube to give a total volume of 25 μl. The final volume contains 50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, and 100 μg/ml BSA as a result of the CutSmart buffer and 10 units of HhaI. After digestion incubation 5 μl of 6x Blue Loading dye (Promega, Madison, WI) containing 0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0) was added to the the reaction tube. 14 μl of this mixture was then loaded onto precast 15 well Novex TBE 20% gel (Thermo Fisher Scientific, Waltham, MA) using a 25 μL Hamilton Syringe. The DNA were then separated by size using electrophoresis for 2 h at 200 V. The gels were run in an XCell SureLock™ Mini-Cell (Invitrogen, Carlsbad, CA) using Novex TBE running buffer (Thermo Fisher Scientific, Waltham, MA). Bands were stained with either 2 μg/ml ethidium bromide (Sigma-Aldrich, St Louis, MO) or SYBR safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, MA) and visualized with an ultraviolet gel imaging system (Syngene, Cambridge, UK).

Amyloid beta and tau staining in human cortical sections {#Sec6}
--------------------------------------------------------

Tissue sections were stained for amyloid beta and tau according to a previous study \[[@CR17]\]. Briefly, fresh post-mortem tissue blocks were fixed in formalin and dehydrated in an ascending alcohol series. Three paraffin waxing stages were performed and 4 μm thick tissue sections were cut on a Leica microtome and collected on glass slides. Immunohistochemistry for amyloid beta (BA4, M087201--2, Agilent) and pTau (AT8, MN1020, Thermo) was performed using the Novolink Polymer detection system and visualized using DAB as chromogen. Images were acquired using an upright Zeiss axioImager equipped with MicroBrightfield stereology software.

Synaptoneurosome preparation {#Sec7}
----------------------------

Brain homogenates and synaptic fractions were prepared as described in Tai et al. 2012 \[[@CR49]\]. In brief, \~ 300 mg of cortical tissue was homogenized on ice in homogenization buffer (25 mM HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl~2~, 2 mM CaCl~2~, protease inhibitors (roche complete mini), phosphatase inhibitors (Millipore, 524,629)). The homogenate was filtered through 2 layers of 80 μm nylon filter (Millipore, NY8002500) and saved as crude homogenate. The crude homogenate was further filtered through a 5 μm filter (Millipore, SLSV025NB) and centrifuged at 1000 *g* for 5 min. The pellet was washed once, then the supernatant was removed and the pellet was resuspended in in label-free buffer \[100 mM Tris-HCl (pH 7.6) 4% (w/v) SDS\] containing 1% protease cocktail inhibitor (Thermo Fisher, UK). Homogenates were centrifuged at 20,000 x g for 20 min at 4 °C with the soluble fraction of each sample transferred to Lo-Bind tubes (Sigma Aldrich). Protein determination using the Bicinchoninic acid assay (Pierce, UK) was carried out according to manufacturer's guidelines.

Electron microscopy {#Sec8}
-------------------

Synaptoneurosome pellets were fixed in 4% paraformaldehyde/ 2% glutaraldehyde in PB for 48 h at 4 °C. Pellets were then post fixed in 1% osmium tetroxide for 30 min, rinsed, and dehydrated in increasing concentrations of ethanol with uranyl acetate 1% in the 70% ethanol step for 1 h. After 100% ethanol, pellets were rinsed in propylene oxide then embedded in Durcupan resin per manufacterers instructions. 70 nm sections were cut on an Ultracut microtome (Leica) with a histo jumbo diamond knife (Diatome) and moutned on 300 mesh copper EM grids (Electron microscopy sciences). Sections were stained with lead citrate in a CO~2~ free environment for 2 min, rinsed in boiled double distilled water, and imaged on a JOEL JEM-1400 transmission electron microscope at an effective magnification of 25,000x-50,000x.

SDS-PAGE and western blotting {#Sec9}
-----------------------------

SDS-PAGE and western blotting were performed as described previously \[[@CR19]\]. Briefly, 5 μg of protein from synaptoneurosome fractions and molecular weight marker (Li-Cor, Cambridge, UK) was loaded onto NuPAGE 4--12% Bis-Tris precast polyacrylamide 15 well gels (Invitrogen, Paisley, UK). Proteins were transferred to polyvinylidene fluoride (PDVF) membranes and blocked using Odyssey Blocking buffer (927--40,000, Li-Cor) diluted 1:1 in PBS. Primary antibodies were incubated overnight in blocking buffer and proteins were detected on an Odyssey system using 680 and 800 IR dye secondary antibodies diluted 1:10000 in blocking buffer (Table [2](#Tab2){ref-type="table"} shows antibodies used in western blots). Total protein stains were performed with Instant Blue total protein stain per manufacturer instructions (Expedeon). Table 2Antibodies used for Western blotsProteinManufacturerCatalogueValidation for WB (from manufacturers website)RRIDActinAbcamAB 8226Cell lysates from HeLa, Jurkat, A431, HEK293, NIH 3 T3, PC12 cells.AB_306371Alpha synucleinSanta CruzSc-7011-RSH-SY5Y cell lysate, α-synuclein expression in mouse and rat brain tissue extracts.AB_2192953Annexin VAbcamAB 54775ANXA5 expression in Hela, 293 T cell line, pentoxifylline cell treatment.AB_940268Beta TubulinAbcamAB 18207HAP1 cell lysate; mouse brain and hippocampus lysates; rat brain lysate; human brain lysate. Knock out cell lines studies.AB_444319GAPDHAbcamAB 9845HeLa, A431, A549, NIH3T3, PC12 whole cell lysateAB_307275GFAPDako/AgilentZ033429--2antibody solid-phase absorbed with human and cow serum proteins. One distinct precipitate (GFAP) with cow brain extract.AB_10013382Histone H3AbcamAb 1791HeLa, Drosophila embryo nuclear extract, NIH/3 T3, S.cerevisiae (Y190) and S.pombe whole cellAB_302613NMDANR2BBD Biosciences610,416Rat NMDA receptorsAB_397796PSD95AbcamAB 18258Mouse and rat brain lysates. PSD95 knockout mouse and immunoprecipitation.AB_444362SNAP25AbcamAB 53723RAW264.7 cell extracts and blocking peptides.AB_882623SOD2novusbioNB100--1992Rat brain tissue extract.AB_535862SynaptophysinAbcamAB 8049Presynaptic vesicles.AB_2198854TMEM97Atlas AntibodiesHPA044795Recombinant expression validation using target protein overexpression.AB_10959306*WB* Western blot, *RRID* Research Resource Identifiers

LC-MS/MS analysis {#Sec10}
-----------------

Pools containing equal amounts of protein (25 μg per case) were prepared of each of the 8 groups (control *APOE3/3* BA41/42, control *APOE3/3* BA17, control *APOE3/4* BA41/42, control *APOE3/4* BA17, AD *APOE3/3* BA41/42, AD *APOE3/3* BA17, AD *APOE3/4* BA41/42, AD *APOE3/4* BA17). Preparation of the samples, quantification, and bioinformatics was carried out according to standardized protocols \[[@CR15], [@CR25], [@CR32]\].

Samples were lysed in 4%SDS + 100 mM tris prior to protein estimation by microBCA. Each sample was then reduced with 100 mM DTT and samples then processed using the FASP protocol \[[@CR56]\] with some modifications. Samples were initially diluted 1:10 into 8 M Urea and buffer exchanged to remove the SDS and tris buffer, filters were then washed 3 times with 100 mM Tris-HCL pH 8 then another 3 times with 100 mM triethyl ammonium bicarbonate (TEAB). Proteins on the filters are then digested twice at 30oc with trypsin (2 x 1μg), first overnight and then for another 6 h in a final volume of 200 μl prior to addition of 200ul of 500 mM NaCl. Samples were then desalted using a SPE cartridge (Empore-C18, Agilent Technologies, 7 mm/3 ml) and the peptides dried in a speedvac (Savant).

Desalted tryptic peptides (25 μg each sample) were then dissolved in 100 μl 100 mM TEAB. The different 8 TMT labels were dissolved in 41 μL of anhydrous acetonitrile, and each label then added to a different sample. The mixtures were incubated for 1 h at room temperature and the labelling reaction was then quenched by adding 8 μL of 5% hydroxylamine. Following labelling with TMT, samples were mixed, desalted using a SPE cartridge (Empore-C18, Agilent Technologies, 7 mm/3 ml) and the peptides dried in a speedvac (Savant). Samples were then dissolved in 200 μL ammonium formate (10 mM, pH 10) and peptides fractionated using High pH RP HPLC. A C18 Column from Waters (XBridge peptide BEH, 130 Å, 3.5 μm 2.1 X 150 mm, Ireland) with a guard column (XBridge, C18, 3.5 μm, 2.1X10mm, Waters) are used on a Ultimate 3000 HPLC (Thermo-Scientific). Buffers A and B used for fractionation consists, respectively of 10 mM ammonium formate in milliQ water and 10 mM ammonium formate with 90% acetonitrile, both buffers were adjusted to pH 10 with ammonia. Fractions were collected using a WPS-3000FC auto-sampler (Thermo-Scientific) at 1 min intervals. Column and guard column were equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.2 ml/min. Samples (175 μl) were loaded onto the column at 0.2 ml/min. Peptides were eluted from the column with a gradient of 2% buffer B to 5%B in 6 min then from 5% B to 60% B in 50 min. The column is washed for 16 min at 100% buffer B and equilibrated at 2% buffer B for 20 min as mentioned above. The fraction collection started 1 min after injection and stopped after 80 min (total of 80 fractions, 200 μl each). The total number of fractions concatenated was set to 20 by non-contiguous pooling and the content of the fractions dried and resuspended in 50 μl of 1% formic acid prior to analysis by nLC-MS/MS.

Analysis of peptides was performed using a Q-Exactive-HF (Thermo Scientific) mass spectrometer coupled with a UltiMate 3000 RSLCnano (Thermo Scientific) UHPLC system. nLC buffers were as follows: buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q water (v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). Aliquots of 15 μL of each sample (50ul in total) were loaded at 5 μL/min onto a trap column (100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) equilibrated in 98% buffer A. The trap column was washed for 6 min at the same flow rate and then the trap column was switched in-line with a Thermo Scientific, resolving C18 column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The peptides were eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 95% buffer A to 40% buffer B in 122 min, and then to 98% buffer B by 132 min. The column was then washed with 95% buffer B for 15 min and re-equilibrated in 98% buffer A for 32 min. Q-Exactive HF was used in data dependent mode. A scan cycle comprised MS1 scan (m/z range from 335 to 1800, with a maximum ion injection time of 50 ms, a resolution of 120,000 and automatic gain control (AGC) value of 3 × 106) followed by 15 sequential dependant MS2 scans (with an isolation window set to 0.7 Da, resolution at 60000, maximum ion injection time at 200 ms and AGC 1 × 105. To ensure mass accuracy, the mass spectrometer was calibrated on the first day that the runs are performed.

The raw mass spectrometric data files obtained for each experiment were collated into a single quantitated dataset using MaxQuant 1.6.0.16 \[[@CR10]\] and Andromeda search engine software \[[@CR11]\] with enzyme specificity set to trypsin. Other parameters used were: (i) variable modifications, deamidation (NQ), oxidation (M), protein N-acetylation, gln-pyro-glu; (ii) fixed modifications, carbamidomethylation (C); (iii) database: uniprot-human_Sept2017 database; (iv) Reporter ion MS2 -- TMT labels: TMT8plex_Nter and TMT 8plex-Lys; (v) MS/MS tolerance: FTMS- 10 ppm, ITMS- 0.02 Da; (vi) maximum peptide length, 6; (vii) maximum missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false discovery rate, 1%. Peptide ratios were calculated using 'Reporter Intensity' Data that was normalised using 1/median ratio value for each identified protein group per labelled sample.

In silico analyses {#Sec11}
------------------

Filtered data was utilised for all bioinformatics statistical analyses and filtered by the following excluding proteins identified by only 1 peptide. For some analyses we filtered for proteins that demonstrated a ± \> 20% change between *APOE3/4* BA41/42 AD and control subjects. The Database for Annotation Visualization and Integrated Discovery (DAVID) was used to test whether synaptic protein sets were enriched in the samples \[[@CR21]\]. To obtain further insight into potential pathways changed in AD synapses, Ingenuity Pathway Analysis (IPA, Ingenuity Systems) was used as previously described \[[@CR15], [@CR32], [@CR55]\] with the interaction data limited as follows: direct and indirect interactions; experimentally observed data only; 35 molecules per network; 10 networks per dataset. Prediction activation scores (z- scores) were calculated in IPA. Expression clustering was performed in Biolayout Express 3D software by applying Markov clustering algorithms to raw proteomic data (MCL 19 2.2) as previously described in \[[@CR32]\]. All graphs were clustered using Pearson correlation *r* = 0.96.

Data sharing {#Sec12}
------------

Unfiltered proteomics data is included as Additional file [5](#MOESM5){ref-type="media"}: Table S5. The mass spectrometry proteomics data have also been deposited to the ProteomeXchange Consortium via the PRIDE partner repository \[[@CR39]\], with the dataset identifier PXD013753. DAVID analysis is provided in Additional file [2](#MOESM2){ref-type="media"}: Table S2. The full IPA analysis from Fig. [3](#Fig3){ref-type="fig"} is in Additional file [3](#MOESM3){ref-type="media"}: Table S3. Complement proteins identified are in Additional file [4](#MOESM4){ref-type="media"}: Table S4. Filtered proteomics data used for IPA analysis in Fig. [3](#Fig3){ref-type="fig"} is provided in Additional file [6](#MOESM6){ref-type="media"}: Table S6.

Results {#Sec13}
=======

Development of a human post-mortem synaptic reference proteome {#Sec14}
--------------------------------------------------------------

To better understand the changes in synapses that may contribute to disease pathogenesis in AD and how the genetic risk factor *APOE* contributes to synaptic vulnerability, we conducted a proteomic study of human post-mortem brain tissue. Using immunohistochemistry, proteomics, and western blots, we examined two brain regions, superior temporal gyrus (BA41/42) which has a severe pathological burden and primary visual cortex (BA17) which is less severely affected even at the end stages of disease (Fig. [1](#Fig1){ref-type="fig"}a and b) \[[@CR45]\]. With this study design incorporating disease, brain region, and *APOE* genotype, it is possible to design a series of comparisons which will enable the interrogation of complex proteomic comparisons in a biologically meaningful way (Fig. [1](#Fig1){ref-type="fig"}c). Through the MRC Edinburgh sudden death brain bank, we were able to access samples from 33 brain tissue donors whose condition and underlying genetics were amenable to this particular investigation. Details of subjects in the study can be found in Table [1](#Tab1){ref-type="table"}. Fig. 1Increased pathology in temporal compared to occipital cortex and in *APOE4* compared to *APOE3* carriers. Representative images of immunohistochemistry for amyloid beta (**a**) tau (**b**) (brown) and Hematoxylin and Eosin counterstain for cells (blue) highlight the higher pathological load in *APOE*4 carriers than *APOE*3 carriers and more pathology in superior temporal gyrus (BA41/42) compared to primary visual cortex (BA17). For analysis, we examined ratios of AD vs control samples in the 2 brain regions and with *APOE*3/3 or *APOE*3/4 genotype to examine how the synaptic proteome changes with differential pathology (**c**). Scale bars represent 200 μm (**a**) 50 μm (**b**)

Synaptic fractions were prepared and quality control for post-mortem protein degradation were confirmed as previously described \[[@CR15], [@CR25], [@CR32]\] (Fig. [2](#Fig2){ref-type="fig"}). Enrichment of synaptic proteins and exclusion of nuclear protein were confirmed by western blot (Fig. [2](#Fig2){ref-type="fig"}a). Any synaptoneurosome preparations containing nuclear histone protein were discarded and fresh preparations made from the same case. Protein degradation was assessed using comparison of total protein stains (Fig. [2](#Fig2){ref-type="fig"}b-d) and using the "HUSPIR" ratio which examines NMDAR2B degradation that occurs postmortem \[[@CR6]\] (Additional file [8](#MOESM8){ref-type="media"}: Figure S2). The HUSPIR ratio significantly correlated with RNA integrity number (*p* = 0.009, *R*^*2*^ = 0.215, linear regression analysis) and brain pH (*p* = 0.023, *R*^*2*^ = 0.184, linear regression analysis) but not at all with post-mortem interval. RIN and pH are routinely collected for all brain bank samples and used as a proxy for tissue integrity. Here we confirm that protein degradation correlates better with these markers than with post-mortem interval highlighting the importance of tissue handling in maintaining protein integrity. Electron microcopy conducted on synaptoneurosome pellets (Fig. [2](#Fig2){ref-type="fig"}e) confirms preservation of pre and postsynaptic terminals in pairs with our synaptoneurosome preparation as we had previously observed \[[@CR49]\]. We observe clear post synaptic densities, presynaptic vesicles, and synaptic mitochondria. Fig. 2Enrichment and integrity analysis of synaptic protein preparations **a**) A representative western blot from 3 cases shows the enrichment of synaptic proteins and exclusions of histones from the synaptoneurosome preparation (P) compared to crude homogenate (H) protein from that sample. Blots were probed for PSD95, synaptophysin, histone and GAPDH. **b** Total protein analysis (TPA) was also used to determine whether any samples showed evidence of protein degradation. Boxes in panel (**b**) indicate the molecular weight ranges analysed for total protein stain. Quantification reveals no difference in total protein in BA17 (**c**) or BA41/42 (**d**) samples (One way ANOVAs, *p* \> 0.05). Transmission electron microscopy confirms that synaptoneurosome preparations contain paired pre and post synaptic terminals as expected (**e**). We observe clear electron dense postsynaptic densities (arrows), presynaptic vesicles (arrowheads), presynaptic mitochondria (m) and small processes associated with synapses (\*). Scale bar represents 500 nm

Having confirmed that the extracted protein is of appropriate quality, we then applied a comprehensive workflow to enable us to assess (at the protein level) the relative contribution of both regional vulnerability and *APOE* variants as a risk factors to AD pathogenesis (Fig. [1](#Fig1){ref-type="fig"}c, Additional file [7](#MOESM7){ref-type="media"}: Figure S1) \[[@CR15], [@CR32]\]. We performed a complex 8-plex TMT LC-MS/MS analysis. Representative pools based on the outlined groupings were generated from these synaptic protein extracts. By pooling individual samples according to *APOE* genotype and cortical area, we were able to reduce potential noise in the system generated through inter individual differences, subtle post mortem handling differences and/or sample isolation \[[@CR16]\]. Thus, 25 μg of each of the 33 subjects were pooled according to disease status, *APOE* genotype (3/3 or 3/4) and brain region (BA41/42 or BA17). The inclusion of an equivalent proportion of each protein isolate into a readily comparable pool allowed the generation of a molecular fingerprint representative of each condition and enables subsequent analysis of individual patient variability in the resulting validatory work (as a deviation from the population signal, as previously described \[[@CR25], [@CR36]\]).

Following detection on the mass spectrometer, quantitation of the dataset using MaxQuant \[[@CR10]\] and Andromeda search engine software \[[@CR11]\] we identified 7148 protein identifications (IDs) in total. These 7148 identified proteins were then filtered to include only proteins identified by 2 or more unique peptides (Fig. [3](#Fig3){ref-type="fig"}c). This yielded 5678 proteins. A DAVID enrichment analysis of this filtered list of proteins served to further confirmed enrichment of the samples for synaptic material (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Fig. 3Synaptic proteomes are altered by AD and *APOE* genotype **a**) Heat map with hierarchical clustering demonstrates the differential abundance of the 5678 individual proteins across "spared" and "vulnerable" brain regions and with *APOE* genotype. The ratios compare AD to control in each condition. **b** Stacked bar chart demonstrates there is a direct correlation between the number of proteins that are differentially expressed, by 20% or more (up or down regulation), with the "vulnerability status' of the synapses as determined by both genotype and brain region. **c** Graphical representation of protein abundance ratios in the comparison AD vs. ctrl (*APOE*3/4, BA41/42) before (left) and after applying the filters of at least 2 unique peptide IDs and \> 20% change between AD and control (right). The dotted lines indicate a change of 20% up or down (note 4 proteins out of 5678 which have abundance ratios higher than 5 are excluded from the graph in panel **c**). Western blot validation from non-demented control (NDC) and AD cases show examples of a synaptic protein that was decreased in the proteomics dataset (SNAP25 **d**, **e**, t-test *p* = 0.08), and a glial protein that was increased in AD (GFAP, **f**, **g**, Mann-Whitney *p* = 0.045). Data in panels **b** and **e** are shown as mean and error bars represent the standard error of the mean. Each dot represents the value from a single case. Normality of data were assessed with Shapiro-Wilks tests. When comparing the ratio of levels of 9 proteins in AD divided by non-demented controls of 9 proteins and comparing these ratios calculated from western blot vs proteomics data (**h**), we observe a significant correlation between ratios measured with the 2 methods (Pearson correlation *R* = 0.72, *p* = 0.03), validating the accuracy of our pooled proteomics method. Full blots of PSD95, alpha synuclein, tubulin, annexin V, SOD2, and TMEM97 are shown in Additional file [9](#MOESM9){ref-type="media"}: Figure S3

Having confirmed that the proteomic data is likely to be representative of the synaptically enriched starting material we then filtered to include only those demonstrating differential abundance of equal to or greater 20 % (up or down regulated) in the comparison AD vs. ctrl in BA41/42 in *APOE4* carriers (Fig. [3](#Fig3){ref-type="fig"}). After applying these further two data filtering steps we obtained a set of 1532 protein IDs identified with high confidence and meeting our differential abundance criteria.

In order to validate the proteomics data, we selected a subset of 9 proteins for western blot analysis in BA41/42 whose levels should be increased or decreased just past our magnitude of change cutoff as this will be more indicative of the sensitivity of the MS than highly up or downregulated proteins. We also selected a protein whose levels was unchanged to use as an internal control (Fig. [3](#Fig3){ref-type="fig"}, Additional file [9](#MOESM9){ref-type="media"}: Figure S3) \[[@CR44]\]. All of the proteins we chose for validation by western blot went in the direction indicated by the proteomics results and the ratios of AD/non-demented control levels in western blots significantly correlated with those found with proteomics (Pearson's correlation *p* = 0.03, details in Fig. [3](#Fig3){ref-type="fig"}).

In silico analysis revealed differences in abundance ratios correlating with increasing vulnerability for AD neuropathology {#Sec15}
---------------------------------------------------------------------------------------------------------------------------

To determine potential differences in the synaptic proteomes of AD patients vs. control subjects dependent on *APOE* genotype and brain region, we focused on the protein abundance ratios as calculated by dividing values from AD patients by matched control subjects, subcategorised for *APOE*3/4 or *APOE*3/3 genotype, and segregated by brain region (Fig. [3](#Fig3){ref-type="fig"}a-c). More proteins were changed in AD patients compared to controls in BA41/42 of *APOE*4 carriers than any other condition (Fig. [3](#Fig3){ref-type="fig"}b). The numbers of protein changes increases progressively from *APOE*3/3 BA17 \< *APOE*3/3 BA41/42 \< *APOE*3/4 BA17 \< *APOE*3/4 BA41/42. Looking at the 15 most upregulated and downregulated pathways detected by Ingenuity Pathway Analysis software (Fig. [4](#Fig4){ref-type="fig"}) reveals that pathways involved in intracellular signalling, glial proteins involved in glia-neuron interactions, and the immune response are upregulated in AD compared to control with generally larger effects in the temporal cortex BA41/42. Downregulated pathways include many involved in synaptic function such as synaptic long term potentiation, glutamate signalling, and calcium signalling. The most downregulated pathway in AD *APOE*3/4 BA/41/42 was oxidative phosphorylation including significant downregulation of proteins in complex I, IV, and V. This pathway was increased in BA17 indicating a potential compensatory effect in BA17 which has less pathology at end stages of disease. This combination of region specific decreases in synaptic and mitochondrial proteins is very interesting in light of our recent paper showing decreased numbers of mitochondria in synaptic terminals in BA41/42 using electron microscopy \[[@CR40]\]. All pathways detected with IPA analysis are available in Additional file [3](#MOESM3){ref-type="media"}: Table S3. Fig. 4Proteins involved in multiple pathways are altered in AD and by APOE genotype and brain region. Using Ingenuity Pathway analysis to investigate pathway alterations in the 1532 proteins that were changed more than 20% in the most vulnerable brain condition (*APOE*3/4 BA41/42) shows that in AD there is a clear upregulation of pathways involved in the immune response and cellular signaling and down regulation of several pathways involved in synaptic function including long term potentiation, glutamate signaling, and calcium ignaling. These pathways were differentially regulated in the different brain regions and *APOE* genotypes. Comparing *APOE*4 to *APOE*3 carriers within the control (con) and AD groups similarly reveals region-specific effects of *APOE* isoform on the synaptic proteome. Z-scores are plotted in d with upregulated proteins shown in red and downregulated in green

Our previous work examining synapses in human post-mortem tissue has revealed that the handling of the body and the tissue is critical for maintaining structural and molecular integrity of synapses \[[@CR26], [@CR40]\]. In particular, we observe that rapid cooling of the body after death preserves synapse structure and molecular integrity better even than short post-mortem intervals. Therefore in this study we used samples only from the Edinburgh MRC Sudden Death Brain Bank whose robust handling protocol is carried out on each individual ensuring that the data is as comparable as possible. This precluded precise age and sex matching of our control groups with our AD groups (see Table [1](#Tab1){ref-type="table"}), which could mean that there are confounding effects of age and sex on our AD/control comparisons. However, when we compare BA41/42 of the AD *APOE*3/4 to AD *APOE*3/3 cases, which are better age and sex matched, we observe many of the same pathways increased in AD *APOE*4 carriers compared to AD *APOE*3 carriers as those we observed in the comparison of AD vs control *APOE*4 carriers (Fig. [4](#Fig4){ref-type="fig"}). Less changes were observed in BA17 from AD *APOE*4 carriers compared to AD *APOE*3 carriers. This strongly supports our conclusion that *APOE*4 influences the synaptic proteome in AD in a region-specific manner. Interestingly, in non-demented controls when *APOE*4 carriers are compared to *APOE*3 carriers in BA41/42, there are changes in the opposite direction to those that are observed in *APOE4* AD vs control.

To further examine trends in protein changes in an unbiased manner, we performed clustering analysis to detect differences in the abundance ratios across these differentially vulnerable synaptic populations. Proteins were clustered according to their abundance profile across the four calculated ratios (Fig. [5](#Fig5){ref-type="fig"}). Each sphere represents an individual protein ID and the distances between the spheres indicate the similarity in abundance profile. Different colours are used to group proteins together in clusters based on abundance profile similarity. In order to analyse the impact/influence of *APOE* genotype and cortical region, we focused specifically on clusters showing a steady increase or decrease in protein abundance across the four groups or only demonstrating differences in protein abundance in *APOE*4 carriers in BA41/42 (Fig. [5](#Fig5){ref-type="fig"}). In order to determine if these abundance profile specific clusters were associated with specific pathways and/or canonical cascades, we have carried out a higher order functional clustering analysis using IPA software. IPA pathway analysis and DAVID enrichment analysis highlighted multiple affected pathways. In clusters 4, 5, 8 and 21 which have progressive decreases in AD/control ratios as pathological severity increases (Fig. [5](#Fig5){ref-type="fig"}), we observe pathways involved in synaptic function are decreased including glutamate signalling, synaptic long term potentiation, GABA receptor signalling, CREB signalling, and synaptic long-term depression. Cluster 6 containing proteins that were sharply decreased in the condition with most pathology, AD *APOE*4 BA41/42, similarly showed decreases in pathways involved in synaptic function including CREB signalling and GABA receptor signalling, along with decreases in pathways implicated in mitochondrial function including oxidative phosphorylation (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Clusters of protein changes. **a** Graphia Professional representation of proteomic abundance data across differentially vulnerable synaptic populations. Each sphere represents a single protein and the edge represents how similar their abundance trend is towards the other proteins in the dataset. The closer the spheres are the more similar the abundance trend. The colours represent the different clusters formed by grouping proteins with similar abundance trends. The resulting profiles were grouped into four different categories as shown in the example graphical abundance trends for further analysis. The annotation associated with each graph represents the cluster numbers which fit each trend and the number of associated proteins. Graphs **b**-**e** show the top pathway changes in the clusters indicated

Interestingly, when examining clusters 7, 9, and 18 which were progressively increased with pathological vulnerability, we observe proteins involved in autophagy and chemokine signalling were progressively upregulated in conditions of higher synaptic vulnerability (Fig. [5](#Fig5){ref-type="fig"}). Clusters 1 and 2, which included proteins highly upregulated in AD *APOE*4 BA41/42 compared to the other groups indicate increases in pathways involved in actin cytoskeleton signalling, NRF2 mediated oxidative stress response, PDGF signalling, and insulin receptor signalling, which all implicate non-neuronal contributors to synapse degeneration as has been recently emphasised for AD risk by genetic studies \[[@CR18]\].

Along with the unbiased bioinformatic analyses, we further interrogated our proteomics dataset to examine proteins of interest based on what is known about synapse degeneration in AD from model systems. In addition to loss of proteins involved in synaptic function in remaining synapses in AD as shown with bioinformatics, it is likely that there is some degree of synaptic remodelling/compensation taking place as some synaptic proteins were increased. The synaptic receptor TMEM97 is increased in remaining synapses in AD vs control *APOE*4 carriers in BA41/42 (Fig. [3](#Fig3){ref-type="fig"}). This is particularly interesting because TMEM97 is the sigma 2 receptor, and compounds that disrupt interaction of Aβ and sigma 2 receptors are protective in mouse models and are being tested for efficacy in human AD as a therapeutic \[[@CR23]\]. Clusterin is also increased 21% in AD compared to controls. This is interesting in light of our recent work showing clusterin within individual synapses containing amyloid beta in human AD brain using high resolution imaging \[[@CR24]\].

Recent data strongly implicate the complement cascade and microglia in Aβ mediated synapse loss in mouse models of amyloid deposition \[[@CR20], [@CR46]\]. Two studies recently demonstrated upregulation of components of the complement system in AD brain and influence of complement cascade in synapse dysfunction and loss in a mouse model of tauopathy \[[@CR12], [@CR31]\]. Based on these data, we interrogated our human synaptoneurosome dataset to look at proteins important for microglial synapse phagocytosis and specifically the complement system. Pathway analysis reveals increases in CD40, IL-6, IL-8, IL-1, IL-2, IL-7 and acute phase response signalling, indicating neuroimmune signalling between neurons and glia in synapses, which is modulated by *APOE* genotype (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). Further interrogation of the proteomics dataset shows increases in C1qA, B, and C in AD brain, which are most pronounced in BA41/42 of *APOE*3 carriers (over 2 fold increases). We also detect complement components C1 and C4 which are increased in most conditions AD brain without a clear effect of *APOE* genotype (Additional file [4](#MOESM4){ref-type="media"}: Table S4).

Discussion {#Sec16}
==========

Of the pathological changes associated with dementia, the best correlate to the extent of memory decline in life is the loss of synapses. Synapses are exquisitely complicated structures requiring thousands of proteins for the complex process of establishing, maintaining, and undergoing synaptic transmission. Work from animal models and human post mortem tissue indicates that synapse degeneration is a driving force in disease progression in AD. However, to date there has been a lack of data on the precise molecular changes in synapses in human AD brain, which impedes the design of hypothesis driven experiments to understand mechanisms of synapse degeneration in animal models that are likely to be relevant to human disease. In the literature, we found 20 publications using proteomics on human AD brain tissue (Additional file [1](#MOESM1){ref-type="media"}: Table S1). In proteomics studies examining whole tissue homogenates from AD brains without considering *APOE* genotype, there have been quite varied results. Three studies show decreases in synaptic proteins or pathways involved in synaptic function, which could have been explained by synapse loss \[[@CR1], [@CR38], [@CR59]\]. To our knowledge only one previous study examined the effects of *APOE* on synaptic proteins \[[@CR53]\]. This study used whole tissue homogenates from AD and control subjects for proteomics but focused their analysis on a group of 191 proteins that had previously been detected in synaptosome fractions of healthy subjects. With this method, they observed a downregulation of glutamate signalling proteins and an effect of *APOE*4 genotype on the abundance of these synaptic proteins. Our results significantly expand upon these findings as we biochemically isolated synaptoneurosomes from AD and control subjects and detected over 5500 proteins, which is over 25 times more proteins examined than in the previous study of synaptic proteins. Synaptoneurosome preparations have not previously been used in proteomic studies of AD. Synaptoneurosomes, unlike other synaptic fractions, contain both the presynaptic and postsynaptic compartments, which is important due to data from model systems implicating both pre and post synapses in degenerative mechanisms. Further, the preparation might retain parts of glial processes closely associated with the synapse, which is key for understanding the role of non-neuronal cells in synapse degeneration, an important topic in the field \[[@CR18]\].

We observed that multiple pathways including those associated with synaptic and mitochondrial function were downregulated with increasing vulnerability and other pathways including intracellular signalling and neuroimmune signalling proteins were increased with increasing vulnerability. This is encouraging as dysfunctional synaptic signalling is consistent with multiple lines of evidence from AD animal models \[[@CR5], [@CR43], [@CR48]\]. Some of the proteins that we observe are reduced in AD synapses have been observed as CSF biomarkers associating with disease. For example, we observe a 25% decrease in neurexin 2 and over 30% decrease in neurogranin abundance in AD *APOE*4 superior temporal gyrus compared to controls, whereas recently published biomarker studies observed increases in neurexin 2 and neurogranin in CSF of people with mild cognitive impairment or AD \[[@CR14], [@CR29], [@CR41]\]. In another study of CSF, a group of 9 synaptic proteins (GluR2, GluR4, Neuroligin-2, Neurexin-3A, Neurexin-2A, Calsynytenin-1, Syntaxin-1B, Thy-1, and VAMP-2) were increased \[[@CR33]\]. Our proteomics data support the notion that proteins may be removed from synapses in AD and at least some of these cleared from the brain via CSF.

In addition to the synaptic signalling pathway changes, we observe interesting changes in immune-related signals in AD synapses. In recent work examining both iPSCs and human brain tissue, *APOE*4 was strongly associated with reduced expression of regulators of synaptic function and increased expression of microglial genes associated with the immune response \[[@CR57]\]. *APOE* has been shown to interact with and modulate the immune and inflammatory system in the brain especially through its interaction with another important AD genetic risk factor *TREM2* \[[@CR4]\]. Our study also found that proteins involved in the immune system and neuroimmune signalling are dysregulated in the AD synapse. Recent evidence has indicated that the complement system of innate immunity, particularly complement components C1q and C3, are involved in synaptic death in mouse models both downstream of Aβ and tau pathology, and that ApoE forms a complex with activated C1q which blocks initiation of the complement cascade \[[@CR12], [@CR20], [@CR31], [@CR46], [@CR58]\]. Our study highlights the importance of these pathways in human AD brain and shows that other proteins in this cascade including complement component C4, HLA-1, and Clusterin are all increased at the synapse in AD presenting innate immunity as an attractive area for further study and therapeutic intervention. Our data indicate that within remaining synapses in human AD brain, *APOE*4 is associated with altered levels of proteins involved in synaptic function and proteins involved in the innate immune system. One possible interpretation of these data supports the hypothesis that microglia are involved in synaptic pruning during disease.

Synapses have high energy demands requiring local mitochondrial ATP production. Both Aβ and tau have been observed in model systems to impact mitochondrial function and the intracellular transport of mitochondria, which impair synaptic function \[[@CR30], [@CR34], [@CR42]\]. And there is some evidence that *APOE*4 can impair mitochondria function in cell culture \[[@CR8]\]. However, the role of *APOE*4 in synaptic mitochondrial function in human brain has not been studied. We observe region and *APOE* specific changes in proteins involved oxidative phosphorylation with a strong decrease in BA41/42 of AD patients that was larger in *APOE*4 carriers than *APOE*3 carriers. Conversely, this pathway was increased in BA17 with the strongest increase in E3 carriers. This could reflect a compensatory increase in mitochondrial function in brain regions that are very early in the disease process. Consistent with the BA41/42 data, we recently observed a decrease in presynaptic terminals containing multiple mitochondria in the temporal cortex of AD patients \[[@CR40]\].

Synaptic degeneration is an important part of AD pathogenesis. Further understanding this process and how to delay and/or halt it may lead us towards important novel therapeutic targets not only for AD but also for other diseases for which synapse loss is an integral or important process. As indicated in Fig. [1](#Fig1){ref-type="fig"}a and as expected from the literature, *APOE4* AD cases have a higher degree of amyloid pathology than *APOE3* AD cases. Our data cannot disentangle whether *APOE4* directly affects the synaptic proteome or does so downstream of increasing pathology. We argue that understanding the differences in synaptic proteome in AD vs control and *APOE4* vs *APOE3* will be an important starting point for future mechanistic experiments looking for therapeutic interventions. By coupling subcellular fractionation with anatomical knowledge of regional vulnerability and human patient genetics we were able to generate the most comprehensive synaptic proteomics profiling datasets from human AD patient samples to date. Importantly, we have determined its accuracy through experimental validation and links to existing published literature on mechanisms and biomarker identification. As an example of the potential utility of such data we were able to begin to uncover how AD and *APOE*4 impact synaptic composition and may be leading to synaptic degeneration. Although in this discussion we have highlighted specific proteins and cascades correlating with regional vulnerability and discussed their potential roles in disease progression and /or regulation this was done to highlight the potential utility of our dataset. There are many other potentially important proteins and pathways in these data to explore in future studies. We have made the data freely available and hope that this will provide a useful resource for other researchers in the field to use at their discretion. The results described here demonstrate that *APOE* genotype has a profound impact on the molecular fingerprint of the synapse and that further understanding of the effects of these protein changes may contribute to our understanding of, and ultimately the development of novel therapies for AD.
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**Additional file 1: Table S1.** Systematic literature search for AD proteomics studies. **Additional file 2: Table S2.** DAVID Analysis confirms enrichment of synaptic proteins. **Additional file 3: Table S3.** IPA analysis output. **Additional file 4: Table S4.** Evidence for alterations in proteins involved in the complement cascade in human AD synapses. **Additional file 5: Table S5.** Proteomics raw data. **Additional file 6: Table S6.** Filtered proteomics data used for IPA analysis in Fig. [3](#Fig3){ref-type="fig"}. **Additional file 7: Figure S1.** Proteomics workflow. Samples were prepared from postmortem tissue and processed for proteomics analysis according to the workflow shown. **Additional file 8: Figure S2.** Protein degradation blot example. Protein degradation blots were completed for all samples using NMDA NR2B antibody (a). The ratio of band 1, which is found in vivo, to band 2, which appears with postmoretem degradation was calculated (b) and samples with a ratio \< 1 were excluded from the study. **Additional file 9: Figure S3.** Validation western blots. Validation western blots (uncropped) of AD vs non demented control (NDC) from BA41/42 of people with *APOE3/4* genotype. Full blots are shown for PSD95 and alpha-synuclein (a), SOD2 (b), annexin V (c), TMEM97 (d), beta tubulin (e), and total protein at high intensity (f) and low intensity (g). Each of the molecular weight ranges in g were quantified for each lane, shown in (h). Comparisons between proteomics and western blot data are shown in i.
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